Anika Therapeutics, Inc. (ANIK) — Analyst outlook / Analyst consensus target is. Based on 6 analyst ratings, the consensus is bullish — 3 Buy, 3 Hold.
Analysts estimate Earnings Per Share (EPS) of $0.10 and revenue of $0.15B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-3.83 vs est $0.10 (missed -3930%). 2025: actual $-0.76 vs est $-0.62 (missed -23.6%). Analyst accuracy: 39%.
ANIK Analyst Ratings
Buy
Based on 6 analysts giving stock ratings to Anika Therapeutics, Inc. in the past 3 months
EPS Estimates — ANIK
39%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$3.83
vs Est $0.10
▼ 102.6% off
2025
Actual –$0.76
vs Est –$0.62
▼ 19.1% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect the company to turn profitable.
Revenue Estimates — ANIK
87%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.120B
vs Est $0.150B
▼ 25.3% off
2025
Actual $0.113B
vs Est $0.111B
▲ 1.6% off
Revenue Trend
Revenue has been relatively flat. Analysts forecast significant revenue growth ahead.
